First Results of a Phase 1 Study Evaluating Safety, PK, PD and Clinical Activity of STC-15, a METTL3 Inhibitor, in Patients with Advanced Malignancies, November 2024, Society of Immunotherapy for Cancer (SITC) 39th Annual Meeting

Kyriakos P. Papadopoulos¹, Justin C Moser², Jordi Rodon³, Yaara Ofir-Rosenfeld⁴, Hendrik Weisser⁴, Melinda Snyder⁴, Tess Schmalbach⁴, Tess Barker⁴, Deepa Deshpande⁴, Ben Skead⁴, Doug Hester², Nidhi Sheth², Pamela Saldana Leon³, Edwin Blanco-Cepeda¹, Oliver Rausch⁴, Josefin-Beate Holz⁴

¹ START San Antonio, San Antonio, TX, US
² HonorHealth Research Institute, Scottsdale, AZ, US
³ Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX, US
⁴ Storm Therapeutics Ltd, Cambridge, Cambridgeshire, UK